Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Zhejiang Taimei Medical Technology Co., Ltd.
浙江太美醫療科技股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2576)

PROPOSED ADOPTION OF THE H SHARE AWARD SCHEME (EXISTING SHARES)

PROPOSED ADOPTION OF THE H SHARE AWARD SCHEME (EXISTING SHARES)

The board (the "**Board**") of directors (the "**Directors**") of Zhejiang Taimei Medical Technology Co., Ltd. (the "**Company**") has resolved to propose the adoption of the H Share Award Scheme (Existing Shares) (the "**Share Award Scheme**") at the Board meeting held on May 18, 2026.

The Share Award Scheme is established for the purpose of further improving and refining the Company's incentive mechanism, motivating the enthusiasm of the Company's employees, effectively aligning the interests of the Company's shareholders (the "**Shareholders**"), the interests of the Company and the personal interests of the Company's employees, and jointly driving the sustainable and healthy development of the Company.

The Share Award Scheme will constitute a share scheme involving existing shares under Chapter 17 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and shall be subject to the applicable requirements under Rule 17.12 of the Listing Rules. It, however, does not constitute a share scheme involving the issue of new shares as referred to in Chapter 17 of the Listing Rules, and as such, does not require Shareholders' approval under the Listing Rules. Nevertheless, according to the articles of association of the Company, the adoption of the Share Award Scheme and related matters shall be subject to the approval of Shareholders by way of special resolutions at a forthcoming extraordinary general meeting of the Company (the "**EGM**").

EGM

The Company will seek Shareholders' approval at the EGM for, among other things, the adoption of the Share Award Scheme and related matters. A circular containing, among other things, a notice of the EGM and details of the proposed adoption of the Share Award Scheme and related matters, will be published in due course.

As at the date of this announcement, the proposed adoption of the Share Award Scheme is subject to the approval of the Shareholders. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Company's securities.

By order of the Board
Zhejiang Taimei Medical Technology Co., Ltd.
Dr. ZHAO Lu
Chairman of the Board

Hong Kong, May 18, 2026

As at the date of this announcement, the Board comprises Dr. ZHAO Lu, Mr. MA Dong, Mr. ZHANG Hongwei, Mr. LU Yiming, Mr. HUANG Yufei and Ms. NI Xiaomei as executive Directors, and Dr. JIANG Xiao, Dr. LI Zhiguo and Mr. FUNG Che Wai Anthony as independent non-executive Directors.